BAYER Company Profile
✉ Email this page to a colleague
What is the competitive landscape for BAYER, and when can generic versions of BAYER drugs launch?
BAYER has one hundred and twenty-four approved drugs.
There are fifty-four US patents protecting BAYER drugs. There is one tentative approval on BAYER drugs.
There are one thousand one hundred and three patent family members on BAYER drugs in sixty countries and one hundred and ninety-eight supplementary protection certificates in twenty countries.
Summary for BAYER
International Patents: | 1103 |
US Patents: | 54 |
Tradenames: | 109 |
Ingredients: | 73 |
NDAs: | 124 |
Patent Litigation for BAYER: | See patent lawsuits for BAYER |
Drugs and US Patents for BAYER
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bayer Pharms | CANDEX | nystatin | LOTION;TOPICAL | 050233-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Bayer Hlthcare | CIPRO | ciprofloxacin hydrochloride | TABLET;ORAL | 019537-001 | Apr 8, 1996 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Bayer Pharms | NEO-CORT-DOME | hydrocortisone; neomycin sulfate | CREAM;TOPICAL | 050237-006 | Jun 5, 1984 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for BAYER
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Bayer Pharms | BAYCOL | cerivastatin sodium | TABLET;ORAL | 020740-003 | Jun 26, 1997 | 5,006,530 | ⤷ Try a Trial |
Bayer Hlthcare | BEYAZ | drospirenone; ethinyl estradiol; levomefolate calcium | TABLET;ORAL | 022532-001 | Sep 24, 2010 | RE37838 | ⤷ Try a Trial |
Bayer Hlthcare | MAGNEVIST | gadopentetate dimeglumine | INJECTABLE;INJECTION | 019596-001 | Jun 2, 1988 | 5,560,903 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for BAYER drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets | 2.5 mg | ➤ Subscribe | 2009-09-04 |
➤ Subscribe | Tablets | 200 mg | ➤ Subscribe | 2014-02-28 |
➤ Subscribe | Tablets | 3 mg/0.03 mg/0.451 mg and 0.451 mg | ➤ Subscribe | 2012-09-28 |
➤ Subscribe | Transdermal System | 0.05 mg/day and 0.1 mg/day | ➤ Subscribe | 2005-09-12 |
➤ Subscribe | Tablets | 3 mg/0.02 mg | ➤ Subscribe | 2006-09-29 |
➤ Subscribe | Injection | 1.6 mg/mL | ➤ Subscribe | 2014-02-07 |
➤ Subscribe | Tablets | 0.5 mg, 1 mg,1.5 mg, 2 mg and2.5 mg | ➤ Subscribe | 2017-10-10 |
➤ Subscribe | Tablets | 0.25 mg/0.5 mg | ➤ Subscribe | 2015-01-08 |
➤ Subscribe | Tablets | 3 mg/0.02 mg/0.451 mg and 0.451 mg | ➤ Subscribe | 2012-11-13 |
➤ Subscribe | Tablets | 5 mg ad 10 mg | ➤ Subscribe | 2009-07-10 |
➤ Subscribe | Tablets | 3 mg; 2 mg/2 mg; 2 mg/3 mg; 1 mg | ➤ Subscribe | 2010-10-22 |
➤ Subscribe | Tablets | 25 mg, 50 mg and 100 mg | ➤ Subscribe | 2005-03-22 |
➤ Subscribe | Tablets | 40 mg | ➤ Subscribe | 2016-09-27 |
➤ Subscribe | Oral Suspension | 250 mg/5 mL and 500 mg/ 5 mL | ➤ Subscribe | 2009-10-16 |
➤ Subscribe | Tablets | 3 mg/0.03 mg | ➤ Subscribe | 2005-01-07 |
➤ Subscribe | Orally Disintegrating Tablets | 10 mg | ➤ Subscribe | 2011-12-22 |
➤ Subscribe | Tablets | 0.5 mg/1 mg | ➤ Subscribe | 2007-12-26 |
➤ Subscribe | Tablets | 3 mg/0.02 mg/0.451 mg and 0.451 mg | ➤ Subscribe | 2011-11-21 |
➤ Subscribe | Tablets | 20 mg | ➤ Subscribe | 2009-03-05 |
International Patents for BAYER Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Portugal | 1986495 | ⤷ Try a Trial |
Austria | E552828 | ⤷ Try a Trial |
Slovenia | 2486942 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for BAYER Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0316633 | 99C0012 | Belgium | ⤷ Try a Trial | PRODUCT NAME: AZELASTINE HYDROCHLORIDE; NAT. REGISTRATION NO/DATE: 31 IS 113 F 13 19981021; FIRST REGISTRATION: GB PL 08336/0083 19980218 |
1380301 | CA 2009 00017 | Denmark | ⤷ Try a Trial | PRODUCT NAME: ETHINYLESTRADIOL (SOM BETADEXCLATHRAT) OG DROSPIRENON; NAT. REG. NO/DATE: 42417 (DK) 20080619; FIRST REG. NO/DATE: NL 33842 20070629 |
2493858 | 20C1028 | France | ⤷ Try a Trial | PRODUCT NAME: DAROLUTAMIDE Y COMPRIS SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET SES ESTERS COUVERTS PAR LE BREVET DE BASE; REGISTRATION NO/DATE: EU/1/20/1432/001 20200330 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.